{"id":54111,"date":"2026-01-14T21:45:08","date_gmt":"2026-01-14T13:45:08","guid":{"rendered":"https:\/\/flcube.com\/?p=54111"},"modified":"2026-01-14T21:45:10","modified_gmt":"2026-01-14T13:45:10","slug":"xellsmart-raises-rmb-400-m-in-series-b-b-and-c1-for-ipsc-parkinsons-therapy-backed-by-3sbio-and-crhc-fund","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54111","title":{"rendered":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund"},"content":{"rendered":"\n<p><strong>Xellsmart<\/strong>, a Suzhou\u2011based stem\u2011cell startup, announced the completion of <strong>RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion)<\/strong> in combined <strong>Series B\/B+ and C1 financing<\/strong> to advance its pipeline of <strong>clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells<\/strong> for treating <strong>Parkinson\u2019s disease<\/strong> and other neurological disorders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-structure\">Financing Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Round<\/th><th>Lead Investor<\/th><th>Co\u2011Leaders \/ Participants<\/th><th>Amount (RMB)<\/th><th>Key Investors<\/th><\/tr><\/thead><tbody><tr><td><strong>Series B\/B+<\/strong><\/td><td><strong>3SBio<\/strong><\/td><td>Tailong VC, Asymchem Labs<\/td><td>~280\u202fmillion<\/td><td>C&amp;D Emerging Industry, Qiming, Lilly Asia, HongShan<\/td><\/tr><tr><td><strong>Series C1<\/strong><\/td><td><strong>CRHC Fund<\/strong><\/td><td>\u2013<\/td><td>~120\u202fmillion<\/td><td>New and existing shareholders<\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td><strong>400\u202fmillion<\/strong><\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Use of Proceeds:<\/strong><\/li>\n\n\n\n<li>Advance universal iPSC\u2011derived cell therapies into <strong>key confirmatory clinical stages<\/strong><\/li>\n\n\n\n<li>Enhance <strong>production and quality control systems<\/strong> for off\u2011the\u2011shelf neural cell drugs<\/li>\n\n\n\n<li>Expand GMP manufacturing capacity and US clinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-pipeline\">Company Profile &amp; Pipeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> <strong>Clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells<\/strong> for neurological diseases<\/li>\n\n\n\n<li><strong>Core Indication:<\/strong> <strong>Parkinson\u2019s disease<\/strong> (PD)<\/li>\n\n\n\n<li><strong>Regulatory Milestones:<\/strong> <strong>8 IND approvals<\/strong> from <strong>NMPA and FDA<\/strong> (China &amp; US)<\/li>\n\n\n\n<li><strong>Clinical Status:<\/strong> <strong>Multiple universal iPSC\u2011derived neural cell candidates<\/strong> in <strong>Phase\u202fI\/II registration trials<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Established GMP\u2011compliant iPSC differentiation and neural cell purification platform<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Parkinson\u2019s Disease Patients<\/strong><\/td><td>3.0\u202fmillion<\/td><td>10.0\u202fmillion<\/td><\/tr><tr><td><strong>Addressable for Cell Therapy (2030E)<\/strong><\/td><td>120,000<\/td><td>400,000<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Levodopa, DBS (symptomatic only)<\/td><td>Levodopa, DBS<\/td><\/tr><tr><td><strong>Gene\/Cell Therapy Penetration<\/strong><\/td><td>&lt;1\u202f%<\/td><td>&lt;1\u202f%<\/td><\/tr><tr><td><strong>Potential Annual Cost (USD)<\/strong><\/td><td>$50,000\u201180,000<\/td><td>$300,000\u2011500,000<\/td><\/tr><tr><td><strong>Market Value (2035E)<\/strong><\/td><td>$6.0\u202fbillion<\/td><td>$120\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BlueRock Therapeutics<\/strong> (Bayer) \u2013 iPSC\u2011derived dopaminergic neurons (Phase\u202fI)<\/li>\n\n\n\n<li><strong>Aspen Neuroscience<\/strong> \u2013 iPSC autologous approach (pre\u2011clinical)<\/li>\n\n\n\n<li><strong>Ci Tian (China)<\/strong> \u2013 Neural stem cells (Phase\u202fI)<\/li>\n\n\n\n<li><strong>CytoMed (Singapore)<\/strong> \u2013 iPSC NK cells (oncology\u2011focused)<\/li>\n<\/ul>\n\n\n\n<p><strong>Differentiation:<\/strong> Xellsmart\u2019s <strong>universal allogeneic<\/strong> approach offers <strong>off\u2011the\u2011shelf availability<\/strong> and <strong>scalable manufacturing<\/strong> vs. autologous competitors, reducing costs and treatment timelines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-position-amp-next-steps\">Strategic Position &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development:<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202fII topline data:<\/strong> Expected Q4\u202f2026<\/li>\n\n\n\n<li><strong>Phase\u202fIII initiation:<\/strong> Q2\u202f2027<\/li>\n\n\n\n<li><strong>NDA submission:<\/strong> Q3\u202f2028 (China), 2029 (US)<\/li>\n\n\n\n<li><strong>Manufacturing Expansion:<\/strong> Suzhou facility upgrade to support <strong>10,000 doses\/year<\/strong> by 2027; US satellite facility planned for 2028<\/li>\n\n\n\n<li><strong>Global Licensing:<\/strong> Management evaluating <strong>ex\u2011China partnerships<\/strong> for US\/EU markets; potential <strong>$500\u202fM\u2011$1\u202fB licensing deal<\/strong> upon Phase\u202fII success<\/li>\n\n\n\n<li><strong>Pipeline Extension:<\/strong> iPSC platform being adapted for <strong>ALS, Huntington\u2019s disease, and stroke<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for Xellsmart\u2019s iPSC platform. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\/B+&#8230;<\/p>\n","protected":false},"author":1,"featured_media":54113,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,77,20,2494],"class_list":["post-54111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-cell-therapy","tag-finance","tag-xellsmart-bio-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\/B+ and C1 financing to advance its pipeline of clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells for treating Parkinson\u2019s disease and other neurological disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54111\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund\" \/>\n<meta property=\"og:description\" content=\"Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\/B+ and C1 financing to advance its pipeline of clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells for treating Parkinson\u2019s disease and other neurological disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54111\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T13:45:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-14T13:45:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xellsmart Raises RMB\u202f400\u202fM in Series B\\\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund\",\"datePublished\":\"2026-01-14T13:45:08+00:00\",\"dateModified\":\"2026-01-14T13:45:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111\"},\"wordCount\":414,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1402-1.webp\",\"keywords\":[\"Biotech\",\"Cell-therapy\",\"Finance\",\"XellSmart Bio-Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54111#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54111\",\"name\":\"Xellsmart Raises RMB\u202f400\u202fM in Series B\\\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1402-1.webp\",\"datePublished\":\"2026-01-14T13:45:08+00:00\",\"dateModified\":\"2026-01-14T13:45:10+00:00\",\"description\":\"Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\\\/B+ and C1 financing to advance its pipeline of clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells for treating Parkinson\u2019s disease and other neurological disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54111\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1402-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1402-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Xellsmart Raises RMB\u202f400\u202fM in Series B\\\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54111#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xellsmart Raises RMB\u202f400\u202fM in Series B\\\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund - Insight, China&#039;s Pharmaceutical Industry","description":"Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\/B+ and C1 financing to advance its pipeline of clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells for treating Parkinson\u2019s disease and other neurological disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54111","og_locale":"en_US","og_type":"article","og_title":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund","og_description":"Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\/B+ and C1 financing to advance its pipeline of clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells for treating Parkinson\u2019s disease and other neurological disorders.","og_url":"https:\/\/flcube.com\/?p=54111","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-14T13:45:08+00:00","article_modified_time":"2026-01-14T13:45:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54111#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54111"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund","datePublished":"2026-01-14T13:45:08+00:00","dateModified":"2026-01-14T13:45:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54111"},"wordCount":414,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp","keywords":["Biotech","Cell-therapy","Finance","XellSmart Bio-Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54111#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54111","url":"https:\/\/flcube.com\/?p=54111","name":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54111#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp","datePublished":"2026-01-14T13:45:08+00:00","dateModified":"2026-01-14T13:45:10+00:00","description":"Xellsmart, a Suzhou\u2011based stem\u2011cell startup, announced the completion of RMB\u202f400\u202fmillion (USD\u202f57.3\u202fmillion) in combined Series B\/B+ and C1 financing to advance its pipeline of clinical\u2011grade, allogeneic, universal iPSC\u2011derived neural cells for treating Parkinson\u2019s disease and other neurological disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54111#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54111"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54111#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp","width":1080,"height":608,"caption":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54111#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xellsmart Raises RMB\u202f400\u202fM in Series B\/B+ and C1 for iPSC Parkinson\u2019s Therapy, Backed by 3SBio and CRHC Fund"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1402-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54111"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54111\/revisions"}],"predecessor-version":[{"id":54114,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54111\/revisions\/54114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54113"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}